NCT06003985|Completed
Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists
Assessment of Preoperative Gastric Content With Ultrasound in Patients Taking GLP1 Agonists
Loading search results
Assessment of Preoperative Gastric Content With Ultrasound in Patients Taking GLP1 Agonists
Sponsor study identifier
observational
354
2 countries
8
Study Start
August 29, 2023
Actual (reported)Primary Completion
January 31, 2025
Actual (reported)Study Completion
February 1, 2025
Actual (reported)The aim of this study is to perform bedside gastric point of care ultrasound (POCUS) exams to assess the gastric volume and content (clear liquids vs solid food) perioperatively in patients who take glucagon-like peptide 1 (GLP-1) agonist medications compared to patients who do not take GLP-1 agonists.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 1, 2025
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 15, 2023
Actual (reported)August 22, 2023
Actual (reported)August 29, 2023
Actual (reported)January 31, 2025
Actual (reported)February 1, 2025
Actual (reported)incidence of delayed gastric emptying
delayed gastric emptying is defined by the presence of either solid food, thick liquids or a specific volume (\>1.5 ml/kg) of clear liquids on gastric ultrasound.
This will be measured pre-operatively in the holding room area.
Nothing by mouth (NPO) intervals
This will be measured pre-operatively in the holding room area.
Presence of gastric peristalsis
This will be measured pre-operatively in the holding room area.
The control group will be comprised of patients who are not currently taking any GLP-1 agonist medications. Controls will receive the ultrasound exam to assess stomach contents.
The GLP-1 agonist intake group will be comprised of patients who are currently taking any GLP-1 agonist medications. This group will receive the ultrasound exam to assess stomach contents.
A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The study population will be comprised of patients scheduled for surgery at HSS who meet the following inclusion criteria and none of the exclusion criteria.
George Washington University Hospital
Washington D.C., District of Columbia, 20037, United States
Mayo Clinic
Jacksonville, Florida, 32224, United States
Albany Medical Center
Albany, New York, 12208, United States
Hospital for Special Surgery
New York, New York, 10021, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Weill Cornell Medicine
New York, New York, 10065, United States
University of Virginia
Charlottesville, Virginia, 22903, United States
Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB, Ho AM, Nersessian RSF, Lima FLM, Silva MV, Mizubuti GB. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023 Aug;87:111091. doi: 10.1016/j.jclinane.2023.111091. Epub 2023 Mar 2.
Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Adv Exp Med Biol. 2021;1307:171-192. doi: 10.1007/5584_2020_496.
Oliver Panzer, MD
Hospital for Special Surgery, Department of Anesthesiology
354 participants (actual enrollment reported by the registry).
First Submitted
August 15, 2023
First Posted
August 22, 2023
Study Start
August 29, 2023
Actual (reported)Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.
Contact the study team to confirm eligibility.
University Health Network
Toronto, Ontario, M5G 2C4, Canada
Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y, Yasu T, Harasawa H. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017 Oct;43(5):430-437. doi: 10.1016/j.diabet.2017.05.009. Epub 2017 Jun 23.
Primary Completion
January 31, 2025
Actual (reported)Study Completion
February 1, 2025
Actual (reported)Last Updated
November 26, 2025
Record last verified: 2024-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: